Furthermore, a recent case report described a patient with KIF5B-RET fusion-positive advanced NSCLC, in whom ctDNA assessment identified a previously undetectable RET-KIF5B fusion during treatment with an oral RET-inhibitor [116]. This evidence concerns the gene KIF5B and non-small cell lung carcinoma.